DR 2313
Alternative Names: DR-2313Latest Information Update: 23 May 2011
At a glance
- Originator Meiji Seika Kaisha
- Developer Meiji Seika Pharma
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 19 Apr 2005 Preclinical trials in Stroke in Japan (unspecified route)
- 16 Dec 2003 No development reported - Preclinical for Stroke in Japan (unspecified route)
- 12 Dec 2000 Preclinical development for Stroke in Japan (Unknown route)